These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 37023836)

  • 1. Prediction and verification of the active ingredients and potential targets of Erhuang Quzhi Granules on non-alcoholic fatty liver disease based on network pharmacology.
    Li S; Wu X; Ma Y; Zhang H; Chen W
    J Ethnopharmacol; 2023 Jul; 311():116435. PubMed ID: 37023836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active ingredients of Erhuang Quzhi Granules for treating non-alcoholic fatty liver disease based on the NF-κB/NLRP3 pathway.
    Li S; Ma Y; Chen W
    Fitoterapia; 2023 Dec; 171():105704. PubMed ID: 37858757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation.
    Zhang X; Gao R; Zhou Z; Sun J; Tang X; Li J; Zhou X; Shen T
    J Ethnopharmacol; 2022 Oct; 296():115405. PubMed ID: 35644437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Effect and Mechanism Prediction of Fuzi-Gancao Herb Couple on Non-alcoholic Fatty Liver Disease (NAFLD) based on Network Pharmacology and Molecular Docking.
    Liu K; Yang X; Zhang G; Xiang Z
    Comb Chem High Throughput Screen; 2024; 27(5):773-785. PubMed ID: 37317908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study on the action mechanism of the Polygonum perfoliatum L. on non-alcoholic fatty liver disease, based on network pharmacology and experimental validation.
    Liu G; Yang L; Tang Y; Lin J; Wang F; Shen J; Chang B; Kong X
    J Ethnopharmacol; 2024 Jan; 319(Pt 3):117330. PubMed ID: 37863399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huanglian-Hongqu herb pair improves nonalcoholic fatty liver disease via NF-κB/NLRP3 pathway in mice: network pharmacology, molecular docking and experimental validation.
    Wang Z; Qiu H; Yang Y; Zhang Y; Mou T; Zhang X; Zhang Y
    Hereditas; 2024 Apr; 161(1):12. PubMed ID: 38566171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of Chaenomelis Fructus in treatment of rheumatoid arthritis based on network pharmacology and experimental verification].
    Duan ZH; Jin C; Deng Y; Liu JL; Wang J; Li SG; Zhou Y
    Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):4852-4863. PubMed ID: 37802827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Ganshuang granules on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification.
    Guoguo Z; Bingjie S; Tianyan Z; Shaoxiu JI; Jingwei LI; Yanni D; Feng L; Dong W
    J Tradit Chin Med; 2024 Feb; 44(1):122-130. PubMed ID: 38213247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment.
    Sun CY; Yang LL; Zhao P; Yan PZ; Li J; Zhao DS
    Hereditas; 2022 Dec; 159(1):44. PubMed ID: 36451177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation.
    Yang R; Yang H; Jiang D; Xu L; Feng L; Xing Y
    PeerJ; 2022; 10():e14171. PubMed ID: 36389420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network pharmacology-based prediction and verification of the active ingredients and potential targets of Huagan Decoction for reflux esophagitis.
    Zhao Y; Cao Y; Yang X; Guo M; Wang C; Zhang Z; Zhang Q; Huang X; Sun M; Xi C; Tangthianchaichana J; Bai J; Du S; Lu Y
    J Ethnopharmacol; 2022 Nov; 298():115629. PubMed ID: 35988839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network pharmacology combines machine learning, molecular simulation dynamics and experimental validation to explore the mechanism of acetylbinankadsurin A in the treatment of liver fibrosis.
    Peng W; Yang Y; Lu H; Shi H; Jiang L; Liao X; Zhao H; Wang W; Liu J
    J Ethnopharmacol; 2024 Apr; 323():117682. PubMed ID: 38169205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An herbal formulation "Shugan Xiaozhi decoction" ameliorates methionine/choline deficiency-induced nonalcoholic steatohepatitis through regulating inflammation and apoptosis-related pathways.
    Wang S; Chen B; Du R; Zhong M; Zhang C; Jin X; Cui X; Zhou Y; Kang Q; Xu H; Li Y; Wu Q; Tong G; Luo L
    J Ethnopharmacol; 2024 Jul; 329():118127. PubMed ID: 38583728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification.
    Zhi G; Shao B; Zheng T; Mu J; Li J; Feng Y; Zhu S; Dang Y; Liu F; Wang D
    Front Pharmacol; 2023; 14():1082451. PubMed ID: 36762105
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations.
    Xu S; Tang L; Qian X; Wang Y; Gong J; Yang H; Su D
    J Food Biochem; 2022 Dec; 46(12):e14419. PubMed ID: 36121703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of Xuebijing Injection in treatment of sepsis-associated ARDS based on network pharmacology and in vitro experiment].
    Ding WC; Chen J; Liao HY; Feng J; Wang J; Zhang YH; Ji XH; Chen Q; Wu XY; Sun ZR; Nie SN
    Zhongguo Zhong Yao Za Zhi; 2023 Jun; 48(12):3345-3359. PubMed ID: 37382018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice.
    Yang H; Wei D; Zhang Y; Jian W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(6):691-708. PubMed ID: 37859322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jingfang granule alleviates Pseudomonas aeruginosa-induced acute lung inflammation through suppression of STAT3/IL-17/NF-κB pathway based on network pharmacology analysis and experimental validation.
    Gu M; Su W; Dai J; Wang J; Jia X; Yao J; Zhang G; Zhu Q; Pang Z
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116899. PubMed ID: 37454750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism of Ganke Granules intervening acute lung injury based on network pharmacology and experimental verification].
    Liang H; Li XY; Zhang XW; Bao YW; Ding ML; Yuan QH; He CS; Zeng N
    Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(8):2197-2209. PubMed ID: 38812235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.